Research analysts covering Polomar Health Services.
Recent press releases and 8-K filings for PMHS.
Polomar Health Services Amends Product Fulfillment and Distribution Agreement
PMHS
New Projects/Investments
Revenue Acceleration/Inflection
- Polomar Health Services, Inc. (PMHS) executed an Amended and Restated Product Fulfillment and Distribution Agreement with ForHumanity, Inc. and Island Group 40, LLC, effective August 19, 2025.
- The agreement grants ForHumanity exclusive marketing rights for PMHS's previously licensed, patent-pending inhalable sildenafil and inhalable eletriptan, with PMHS's wholly-owned subsidiary responsible for fulfilling prescriptions.
- The initial term of the Amended Agreement is 42 months, commencing March 17, 2025, and terminating September 16, 2028.
- ForHumanity's exclusivity to market the products is granted through March 31, 2026, in exchange for guaranteed payments of $750,000, of which $200,000 has been received by PMHS.
- Exclusivity may be extended through September 30, 2026, if ForHumanity remits a minimum of $1,500,000 in sales revenue to PMHS prior to March 31, 2026, and can be maintained through December 31, 2026, if PMHS receives at least $3,000,000 in revenue prior to June 30, 2026.
Aug 29, 2025, 8:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more